BPC-157 Dosage Calculator Guide: Reconstitution, Syringe Units & Research Protocol

BPC-157 dosage guide: standard research doses (200–500 mcg/day), reconstitution math for 5mg vials, half-life timing, and a pre-filled syringe calculator.

TL;DR

• BPC-157 is a 15-amino acid synthetic peptide studied for tissue repair, gut healing, and musculoskeletal recovery
• Typical research dose: 200–500 mcg per day, usually split into 2 injections
• Standard reconstitution: 5 mg vial + 2 mL BAC water = 2,500 mcg/mL
• At 2,500 mcg/mL, a 250 mcg dose = 0.1 mL = 10 units on a U-100 syringe
• Half-life ~4 hours — twice-daily dosing maintains more consistent plasma levels
• Calculate your BPC-157 dose →

Disclaimer: BPC-157 is not FDA-approved for human use. For educational and research purposes only — not medical advice.

BPC-157 is reconstituted from a lyophilized vial using bacteriostatic water (BAC water). The most common setup is 5 mg dissolved in 2 mL BAC water, yielding a concentration of 2,500 mcg/mL. At that concentration, a 250 mcg dose = 10 units on a U-100 insulin syringe. Use the pre-filled calculator above or keep reading for the full breakdown.

How Many Units Is a BPC-157 Dose?

The syringe units for any BPC-157 dose depend entirely on how the vial was reconstituted. The table below covers the 4 most common setups:

All unit values assume a standard U-100 insulin syringe (100 units = 1 mL).

Pre-filled BPC-157 calculator: 5mg / 2mL / 250mcg →

Typical BPC-157 Research Doses

In published preclinical literature, BPC-157 is most commonly administered at 1–10 mcg/kg in rodent models. Applying standard allometric scaling to larger research models, the most frequently referenced range is 200–500 mcg per day.

200 mcg/day is the conservative starting point. This dose is used in systemic protocols and in research subjects with lower body weight. It represents the threshold at which measurable effects on tissue repair markers have been observed in the animal model literature, making it the preferred initiation dose in new research programs.

250–300 mcg/day is the most commonly used mid-range dose. At the standard 2,500 mcg/mL reconstitution, 250 mcg = exactly 10 units on a U-100 syringe — a round, easy-to-measure draw volume that minimizes measurement error in daily protocols.

500 mcg/day is used in protocols targeting acute injury or more severe tissue damage. Studies on Achilles tendon transection, ligament repair, and gut mucosal damage have used doses at or near this ceiling. It is the upper boundary for most published research protocols.

Administration route matters in BPC-157 research. Two approaches dominate the literature:

1. Subcutaneous injection near the injury site — The majority of musculoskeletal repair studies (tendon, ligament, bone) use localized SubQ injection adjacent to the target tissue. The rationale is to maximize peptide concentration at the intended site of action.

2. Systemic subcutaneous or intraperitoneal injection — Research questions involving gut healing, neurological protection, or systemic vascular effects typically use a distal injection site. Intraperitoneal administration is common in rodent gastroprotection models.

Cycle length in the published literature ranges from 2–4 weeks for acute injury models up to 8–12 weeks for chronic condition research. No significant adverse findings have been reported in animal models at research-relevant doses over these durations. Given BPC-157's short half-life, splitting the daily dose into 2 equal administrations is standard in protocols requiring consistent plasma levels.

BPC-157 Half-Life and Dosing Frequency

BPC-157 has an estimated half-life of approximately 4 hours based on pharmacokinetic data from animal studies. This is short relative to once-weekly peptides like semaglutide or tirzepatide, and it has a direct practical impact on how protocols are structured.

With a 4-hour half-life, plasma levels peak within a few hours of injection and fall to near-zero within 12–16 hours from a single daily dose. For 16+ hours of each day, systemic exposure would be minimal under a once-daily protocol. This is acceptable when the research goal involves a transient local effect — for example, a single high-concentration pulse near an injury site — but it is suboptimal for studies requiring sustained systemic presence, such as gastrointestinal mucosal protection or neurological effect research.

Twice-daily dosing (splitting the total daily dose into 2 equal injections approximately 10–12 hours apart) is the standard protocol for maintaining more consistent plasma levels. A 500 mcg/day protocol becomes 2 × 250 mcg injections: one in the morning, one in the evening.

For protocols where precise plasma-level timing is critical, a half-life calculator can model the decay curve between doses and help optimize injection timing relative to the research endpoint being measured.

Mechanism of Action

BPC-157 does not bind to a single characterized receptor in the way that GLP-1 agonists bind the GLP-1R. Its effects emerge from interactions with several overlapping biological pathways. Three mechanisms are most consistently supported in the published literature:

VEGF (Vascular Endothelial Growth Factor) Upregulation. Multiple studies have demonstrated that BPC-157 upregulates VEGF expression, promoting angiogenesis — the formation of new blood vessels. Improved vascular supply accelerates oxygen and nutrient delivery to damaged tissues. In tendon injury models, increased vascular ingrowth correlated with faster histological and functional recovery. This mechanism is considered a primary driver of the compound's tissue-healing properties and explains its broad applicability across multiple tissue types that share the same fundamental need for vascularization during repair.

Nitric Oxide (NO) Synthesis Modulation. BPC-157 interacts with the nitric oxide system in a context-dependent manner: upregulating NO production in certain settings while protecting against NO-mediated damage in others. This dual behavior is particularly relevant in gastrointestinal research, where mucosal damage from NSAIDs, alcohol, or ischemia is frequently mediated by NO system disruption. BPC-157 has consistently attenuated this damage in animal models, and the NO pathway is the most cited mechanistic explanation.

Tendon and Ligament Fibroblast Stimulation. Research on Achilles tendon transection models and medial collateral ligament injuries found that BPC-157 significantly accelerated the proliferation and organization of fibroblasts — the cells responsible for producing collagen and remodeling the extracellular matrix. This represents a direct cellular effect on connective tissue that is distinct from the angiogenesis pathway. Histological analyses in these studies showed improved collagen fiber alignment and maturation in BPC-157-treated animals versus controls.

Additional mechanisms under active investigation include growth hormone receptor signaling modulation, FAK (focal adhesion kinase) pathway involvement, and interactions with dopamine and serotonin neurotransmitter systems. The latter may explain neuroprotective effects observed in some CNS injury models, including traumatic brain injury and spinal cord damage research. These secondary mechanisms are less characterized than the three above but represent active areas of BPC-157 research interest.

The pleiotropic activity of BPC-157 — operating across vascular, connective tissue, gastrointestinal, and neurological systems — is what distinguishes it from more targeted peptides and accounts for both its broad research footprint and the complexity of attributing any single observed effect to a single mechanism.

Storage and Handling

Proper storage maintains peptide integrity throughout a research study. Errors here can silently degrade a vial without visible signs, introducing systematic dosing error across an entire protocol.

Lyophilized (freeze-dried) BPC-157 powder should be stored at -20°C for long-term storage. If the vial will be used within 2–3 months, storage at 4°C (refrigerator) is acceptable. Protect from light and moisture regardless of storage temperature. Lyophilized BPC-157 is more stable than most peptides and does not require the ultra-low temperatures (-80°C) that some compounds need.

Reconstituted BPC-157 (in BAC water) should be stored at 4°C and protected from light. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which allows the reconstituted solution to remain stable for approximately 4–6 weeks under proper refrigeration. Do not freeze a reconstituted solution — freezing can cause peptide aggregation and degradation that cannot be reversed by thawing.

Before each use, inspect the solution visually. A properly stored BPC-157 solution should be clear and colorless. Cloudiness, particulate matter, or any color change indicates possible degradation or contamination — do not use. Label each reconstituted vial with the reconstitution date and calculated concentration to maintain accurate dosing records throughout the study.

Frequently Asked Questions About BPC-157

Q: How many units is 250 mcg of BPC-157 on a U-100 syringe? A: It depends on your reconstitution ratio. With the standard 5 mg + 2 mL BAC water setup (2,500 mcg/mL), a 250 mcg dose = 0.1 mL = 10 units on a U-100 insulin syringe. If you reconstituted with 1 mL (5,000 mcg/mL), the same dose = 5 units. The table in this article covers the 4 most common reconstitution setups. The pre-filled calculator handles any custom combination automatically.

Q: What do I use to reconstitute BPC-157? A: BPC-157 is reconstituted with bacteriostatic water (BAC water). BAC water contains 0.9% benzyl alcohol as a preservative, which allows the reconstituted solution to remain stable for 4–6 weeks at 4°C. Do not use sterile water (no preservative, degrades faster) or saline (not appropriate for the initial reconstitution). Inject the BAC water slowly down the side of the vial, swirl gently — never shake — and let sit briefly if needed until fully dissolved.

Q: How long does a reconstituted BPC-157 vial last? A: A BPC-157 vial reconstituted with bacteriostatic water and stored at 4°C (refrigerator) is stable for approximately 4–6 weeks. Exposure to light, heat, or repeated freeze-thaw cycles will shorten this. Label the vial with the reconstitution date and discard after 6 weeks regardless of remaining volume. Never freeze a reconstituted solution — freezing causes aggregation that cannot be reversed.

Q: What is the half-life of BPC-157? A: BPC-157 has an estimated half-life of approximately 4 hours based on pharmacokinetic data from animal models. This is why twice-daily dosing (splitting the daily dose into a morning and evening injection) is standard in protocols requiring consistent systemic levels. For localized acute injury research, once-daily administration near the target site is also used.

Q: Can BPC-157 be stacked with TB-500? A: BPC-157 and TB-500 (thymosin beta-4) are frequently used together in research because they operate through complementary mechanisms: BPC-157 works primarily via VEGF upregulation, NO modulation, and fibroblast stimulation; TB-500 works via actin sequestration and cytoskeletal remodeling. TB-500 also has a significantly longer half-life (~multi-day) supporting twice-weekly dosing versus BPC-157's twice-daily requirement. The compounds are not interchangeable — they are considered additive in tissue repair research contexts. Both are administered as separate injections; mixing in the same syringe is not standard practice.

Ready to calculate your BPC-157 dose?

→ Open BPC-157 in the Reconstitution Calculator

→ View BPC-157 in the Compound Database

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions